• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

淋巴结评估标准对临床IA期肺腺癌和肺鳞癌患者肺切除手术的影响。

Impact of lymph node evaluation standard in patients undergoing lung resection for clinical stage IA pulmonary adenocarcinoma and squamous cell carcinoma.

作者信息

Rocco Raffaele, Hendriksen Brandon S, Ortiz Belisario A, Shen K Robert, Cassivi Stephen D, Saddoughi Sahar, Reisenauer Janani S, Wigle Dennis A, Tapias Luis F

机构信息

Division of Thoracic Surgery, Department of Surgery, Mayo Clinic, Rochester, MN, USA.

出版信息

J Thorac Dis. 2024 Nov 30;16(11):7663-7674. doi: 10.21037/jtd-24-971. Epub 2024 Nov 11.

DOI:10.21037/jtd-24-971
PMID:39678860
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11635252/
Abstract

BACKGROUND

The American College of Surgeons Commission on Cancer (CoC) revised operative quality standards recommending resection of lymph nodes from at least one hilar station and three different mediastinal stations in all curative-intent pulmonary resections. This study evaluated the prognostic value and factors associated with adherence to this new CoC standard in patients with resected clinical stage IA non-small cell lung cancer (NSCLC).

METHODS

Retrospective review of 654 patients who underwent pulmonary resection for clinical IA NSCLC. The study population was divided into patients that met and did not meet the CoC standard.

RESULTS

The CoC standard was met in only 254 (38.8%) patients. Factors associated with meeting the CoC standard included left-sided resections, open technique, and type of pulmonary resection. CoC standard was met in 51.6% of lobectomies, 29.9% of segmentectomies, and 17.1% of wedge resections (P<0.001). Nodal upstaging was more frequent in patients meeting the CoC standard (21.3% 12.5% when standard not met; P=0.004). Time to recurrence [adjusted hazard ratio (aHR): 0.86, 95% confidence interval (CI): 0.63-1.17, P=0.33] and overall survival (aHR: 0.78, 95% CI: 0.58-1.05, P=0.10) were not different between CoC standard groups. However, patients not meeting the CoC standard and classified as pN0 exhibited an overall survival that resembled that of patients with pN1 disease.

CONCLUSIONS

Left-sided resections, open technique and lobectomy were associated with meeting the CoC standard. However, this standard did not have a significant impact on long-term outcomes. Larger studies with longer follow-up are needed to clarify the role of the CoC standard in patients with resected stage IA NSCLC.

摘要

背景

美国外科医师学会癌症委员会(CoC)修订了手术质量标准,建议在所有根治性意图的肺切除术中,至少从一个肺门站和三个不同的纵隔站切除淋巴结。本研究评估了接受手术切除的临床IA期非小细胞肺癌(NSCLC)患者遵守这一新CoC标准的预后价值及相关因素。

方法

回顾性分析654例行临床IA期NSCLC肺切除术的患者。研究人群分为符合和不符合CoC标准的患者。

结果

仅254例(38.8%)患者符合CoC标准。与符合CoC标准相关的因素包括左侧切除术、开放技术和肺切除类型。肺叶切除术患者中51.6%符合CoC标准,肺段切除术患者中29.9%符合,楔形切除术患者中17.1%符合(P<0.001)。符合CoC标准的患者中淋巴结分期上调更常见(符合标准时为21.3%,不符合标准时为12.5%;P=0.004)。CoC标准组之间的复发时间[调整后风险比(aHR):0.86,95%置信区间(CI):0.63 - 1.17,P=0.33]和总生存期(aHR:0.78,95%CI:0.58 - 1.05,P=0.10)无差异。然而,不符合CoC标准且分类为pN0的患者的总生存期与pN1疾病患者相似。

结论

左侧切除术、开放技术和肺叶切除术与符合CoC标准相关。然而,该标准对长期预后没有显著影响。需要进行更大规模、更长随访时间的研究来阐明CoC标准在接受手术切除的IA期NSCLC患者中的作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0208/11635252/f079f04cea20/jtd-16-11-7663-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0208/11635252/3901916cb4e7/jtd-16-11-7663-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0208/11635252/f3a38f1a92e1/jtd-16-11-7663-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0208/11635252/700362962a21/jtd-16-11-7663-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0208/11635252/f079f04cea20/jtd-16-11-7663-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0208/11635252/3901916cb4e7/jtd-16-11-7663-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0208/11635252/f3a38f1a92e1/jtd-16-11-7663-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0208/11635252/700362962a21/jtd-16-11-7663-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0208/11635252/f079f04cea20/jtd-16-11-7663-f4.jpg

相似文献

1
Impact of lymph node evaluation standard in patients undergoing lung resection for clinical stage IA pulmonary adenocarcinoma and squamous cell carcinoma.淋巴结评估标准对临床IA期肺腺癌和肺鳞癌患者肺切除手术的影响。
J Thorac Dis. 2024 Nov 30;16(11):7663-7674. doi: 10.21037/jtd-24-971. Epub 2024 Nov 11.
2
Association of Pathologic Nodal Staging Quality With Survival Among Patients With Non-Small Cell Lung Cancer After Resection With Curative Intent.具有治愈意图的非小细胞肺癌切除术后病理淋巴结分期质量与生存的相关性研究。
JAMA Oncol. 2018 Jan 1;4(1):80-87. doi: 10.1001/jamaoncol.2017.2993.
3
Wedge Resection vs Lobectomy for Clinical Stage IA Non-Small Cell Lung Cancer With Occult Lymph Node Disease.楔形切除术与肺叶切除术治疗隐匿性淋巴结疾病的ⅠA 期非小细胞肺癌的比较。
Ann Thorac Surg. 2023 Jun;115(6):1344-1351. doi: 10.1016/j.athoracsur.2022.08.044. Epub 2022 Sep 17.
4
Assessment of Updated Commission on Cancer Guidelines for Intraoperative Lymph Node Sampling in Early Stage NSCLC.对癌症委员会关于早期非小细胞肺癌术中淋巴结采样的更新指南的评估
J Thorac Oncol. 2022 Nov;17(11):1287-1296. doi: 10.1016/j.jtho.2022.08.009. Epub 2022 Aug 30.
5
Long-Term Results for Clinical Stage IA Lung Cancer: Comparing Lobectomy and Sublobar Resection.临床ⅠA 期肺癌的长期结果:肺叶切除术与亚肺叶切除术比较。
Ann Thorac Surg. 2018 Aug;106(2):375-381. doi: 10.1016/j.athoracsur.2018.02.049. Epub 2018 Mar 23.
6
Sublobar resections in stage IA non-small cell lung cancer: segmentectomies result in significantly better cancer-related survival than wedge resections.IA期非小细胞肺癌的肺叶下切除:肺段切除术相比楔形切除术,癌症相关生存率显著更高。
Eur J Cardiothorac Surg. 2008 Apr;33(4):728-34. doi: 10.1016/j.ejcts.2007.12.048. Epub 2008 Feb 7.
7
Central tumour location should be considered when comparing N1 upstaging between thoracoscopic and open surgery for clinical stage I non-small-cell lung cancer.在比较胸腔镜手术和开放手术治疗临床I期非小细胞肺癌时N1分期上调情况时,应考虑肿瘤的中心位置。
Eur J Cardiothorac Surg. 2016 Jul;50(1):110-7. doi: 10.1093/ejcts/ezv489. Epub 2016 Jan 27.
8
Lobe-specific lymph node sampling is associated with lower risk of cancer recurrence.特定肺叶淋巴结取样与癌症复发风险较低相关。
JTCVS Open. 2023 Nov 23;17:271-283. doi: 10.1016/j.xjon.2023.11.009. eCollection 2024 Feb.
9
A standardized technique of systematic mediastinal lymph node dissection by video-assisted thoracoscopic surgery (VATS) leads to a high rate of nodal upstaging in early-stage non-small cell lung cancer.一种通过电视辅助胸腔镜手术(VATS)进行系统性纵隔淋巴结清扫的标准化技术,在早期非小细胞肺癌中导致较高的淋巴结分期上调率。
Surg Endosc. 2016 Mar;30(3):1119-25. doi: 10.1007/s00464-015-4312-9. Epub 2015 Jul 14.
10
Lobectomy plus lobe-specific lymphadenectomy as the minimum standards of curative resection for hypermetabolic clinical stage IA non-small cell lung cancer.肺叶切除术加肺叶特异性淋巴结清扫术作为高代谢临床ⅠA期非小细胞肺癌根治性切除的最低标准。
Transl Lung Cancer Res. 2025 Jan 24;14(1):14-26. doi: 10.21037/tlcr-24-804. Epub 2025 Jan 22.

本文引用的文献

1
Alectinib in Resected -Positive Non-Small-Cell Lung Cancer.阿来替尼治疗可切除阳性非小细胞肺癌。
N Engl J Med. 2024 Apr 11;390(14):1265-1276. doi: 10.1056/NEJMoa2310532.
2
Video-Assisted Thoracoscopic or Open Lobectomy in Early-Stage Lung Cancer.胸腔镜辅助或开放性肺叶切除术治疗早期肺癌。
NEJM Evid. 2022 Mar;1(3):EVIDoa2100016. doi: 10.1056/EVIDoa2100016. Epub 2022 Jan 18.
3
A National Survey of Surgeons Evaluating the Accuracy of Mediastinal Lymph Node Identification.一项评估纵隔淋巴结识别准确性的外科医生全国性调查。
Clin Lung Cancer. 2023 Jul;24(5):445-452. doi: 10.1016/j.cllc.2023.03.005. Epub 2023 Mar 21.
4
Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer.肺段或亚肺叶切除术治疗外周型ⅠA 期非小细胞肺癌。
N Engl J Med. 2023 Feb 9;388(6):489-498. doi: 10.1056/NEJMoa2212083.
5
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial.帕博利珠单抗对比安慰剂作为完全切除的 IB 期-IIIA 期非小细胞肺癌的辅助治疗(PEARLS/KEYNOTE-091):一项随机、三盲、III 期试验的中期分析。
Lancet Oncol. 2022 Oct;23(10):1274-1286. doi: 10.1016/S1470-2045(22)00518-6. Epub 2022 Sep 12.
6
Station 3A lymph node dissection does not improve long-term survival in right-side operable non-small-cell lung cancer patients: A propensity score matching study.3A 站淋巴结清扫术不能提高可手术的右侧非小细胞肺癌患者的长期生存率:一项倾向评分匹配研究。
Thorac Cancer. 2022 Aug;13(15):2106-2116. doi: 10.1111/1759-7714.14456. Epub 2022 Jun 15.
7
Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial.小型周围型非小细胞肺癌的肺段切除术与肺叶切除术比较(JCOG0802/WJOG4607L):一项多中心、开放标签、3期、随机、对照、非劣效性试验
Lancet. 2022 Apr 23;399(10335):1607-1617. doi: 10.1016/S0140-6736(21)02333-3.
8
Technical Standards for Cancer Surgery: Commission on Cancer Standards 5.3-5.8.癌症手术技术标准:肿瘤委员会标准 5.3-5.8。
Ann Surg Oncol. 2022 Oct;29(11):6549-6558. doi: 10.1245/s10434-022-11375-w. Epub 2022 Feb 20.
9
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.辅助阿特珠单抗治疗辅助化疗后切除的 IB-IIIA 期非小细胞肺癌(IMpower010):一项随机、多中心、开放标签、III 期临床试验。
Lancet. 2021 Oct 9;398(10308):1344-1357. doi: 10.1016/S0140-6736(21)02098-5. Epub 2021 Sep 20.
10
Osimertinib in Resected -Mutated Non-Small-Cell Lung Cancer.奥希替尼治疗可切除突变型非小细胞肺癌。
N Engl J Med. 2020 Oct 29;383(18):1711-1723. doi: 10.1056/NEJMoa2027071. Epub 2020 Sep 19.